The Memory Impairment drugs in development market research report provides comprehensive information on the therapeutics under development for Memory Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Memory Impairment. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Memory Impairment - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Memory Impairment and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Memory Impairment by 12 companies/universities/institutes. The top development phase for Memory Impairment is preclinical with eight drugs in that stage. The Memory Impairment pipeline has nine drugs in development by companies and four by universities/ institutes. Some of the companies in the Memory Impairment pipeline products market are: Dart NeuroScience, Calico Life Sciences and M et P Pharma.

The key targets in the Memory Impairment pipeline products market include Phosphodiesterase 4 (PDE4 or EC 3.1.4.53), Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7), and Amine Oxidase [Flavin Containing] B (Monoamine Oxidase Type B or MAOB or EC 1.4.3.4).

The key mechanisms of action in the Memory Impairment pipeline product include Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Inhibitor with two drugs in Preclinical. The Memory Impairment pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Memory Impairment pipeline products market including Small Molecule.

Memory Impairment overview

Memory impairment or memory loss refers to unusual forgetfulness. The person may not be able to remember new events, recall one or more memories of the past, or both. It can occur for a short time and then resolve (transient), or it can persist, and, depending on the cause, worsen over time.

For a complete picture of Memory Impairment’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.